According to current data, there are significant variations in the severity of psoriasis between racial and ethnic groups. While the Latino community in the United States is quickly expanding, little study has been conducted on the different factors influencing illness severity in this minority population. This review assesses the existing evidence on psoriasis among Latinos in the United States. Psoriasis affects the Latino community in the United States at a lower prevalence, with more severe illness and a larger impact on quality of life than their White counterparts. Furthermore, as compared to Whites, Latinos with psoriasis have greater incidence of comorbidities such as depression, obesity, and diabetes. In this population, there is evidence of non-inferior or superior response to systemic therapies such as etanercept, secukinumab, and brodalumab. The present understanding of the processes responsible for pathologic outcomes and environmental and social inequalities is limited by a combination of obstacles to care and a lack of participation in research.
Future research that represents the expanding minority population in the United States may assist to bridge these information gaps and enhance service.
Reference:https://link.springer.com/article/10.1007/s40257-019-00498-8
